These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17018774)

  • 1. Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?
    Fojo T
    J Natl Cancer Inst; 2006 Oct; 98(19):1345-7. PubMed ID: 17018774
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
    Kanakkanthara A; Teesdale-Spittle PH; Miller JH
    Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
    Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
    Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
    Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
    Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
    Tripathi S; Srivastava G; Sharma A
    Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-gamma inhibitors as novel tubulin-targeting agents.
    Schaefer KL
    Expert Opin Investig Drugs; 2007 Jul; 16(7):923-6. PubMed ID: 17594179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HSP27 phosphorylation induced by microtubule interfering agents: implication of p38 signalling pathway.
    Casado P; Zuazua-Villar P; Prado MA; Valle ED; Iglesias JM; Martínez-Campa C; Lazo PS; Ramos S
    Arch Biochem Biophys; 2007 May; 461(1):123-9. PubMed ID: 17367746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.